medicin compani announc fda approv raplixa fibrin sealant first powder fibrin sealant readytous mild moder surgic bleed medicin compani nasdaqmdco announc today us food drug administr fda approv raplixa fibrin sealant raplixaspray devic provid adjunct hemostasi mild moder bleed adult undergo surgeri control bleed standard surgic techniqu sutur ligatur cauteri ineffect impracticalaccord im data estim everi year approxim 26 3 million surgic procedur requir use topic hemostat product usraplixa requir thaw reconstitut mix appli either direct vial raplixaspray devic devic lowpressur spray applic design deliv raplixa larger bleed surfac difficult reach area control mild moder bleed surgeri requir hemostat agent easytous work well across rang bleed set said grant v bochicchio md mph fac washington univers school medicin st loui mo raplixa raplixaspray devic provid surgeon potenti offtheshelf solut readi address challeng bleed situat encount everi dayth addit raplixa hemostasi portfolio demonstr commit surgeri periop care help improv pathway care surgic patient said clive meanwel md phd chairman ceo medicin compani believ surgeon find raplixa meaning addit surgic practic approv raplixa base one larg phase 3 multicent clinic trial involv 721 patient four countri trial demonstr raplixa use conjunct absorb gelatin spong superior achiev hemostasi compar treatment spong alon use adjunct hemostasi patient undergo vascular hepat spinal soft tissu surgeri advers event general similar treatment group consist observ patient undergo surgeri compani discuss approv quarter earn call may 5that 830 confer call avail via phone webcast dial inform list domest dialin 1 877 3599508 intern dialin 1 dialin number 22764656 replay avail 1130 eastern time follow confer call may 12 2015 hear replay call dial 1 855 8592056 domest 1 404 5373406 intern passcod dialin number 22764656 call webcast access via medicin compani websit raplixa fibrin sealantraplixa fibrin sealant compris humanplasma deriv fibrinogen thrombin indic provid adjunct hemostasi mild moder bleed adult undergo surgeri control bleed standard surgic techniqu sutur ligatur cauteri ineffect impract import safeti informationdo use raplixa intravascular use raplixa treatment sever brisk arteri bleed use raplixa patient known anaphylact sever system reaction human blood productsth intravascular applic raplixa may result thromboembol event air gas embol occur use air gaspressur sprayer administ fibrin sealant raplixaspray devic must oper accord manufactur instruct raplixa may carri risk transmit infecti agent virus theoret creutzfeldtjakob diseas cjd agent despit manufactur step design reduc risk viral transmiss use raplixa may result allerg type hypersensit reaction allerg type hypersensit symptom occur discontinu administr raplixa immedi common report advers reaction 5 patient treat raplixa procedur pain nausea constip pyrexia hypotensionabout medicin companythemedicin companyspurpos save live allevi suffer contribut econom healthcar focus 3000 lead acuteintens care hospit worldwid vision lead provid solut three area serious infecti diseas care acut cardiovascular care surgeri periop care compani oper theamericaseuropeand themiddl east andasia pacif region global center today inparsippani nj usa andzurichswitzerlandforwardlook statementsstat contain press releas medicin compani pure histor statement pure histor may deem forwardlook statement purpos safe harbor provis privat secur litig reform act 1995 without limit forego word believ anticip expect hope potenti similar express intend identifi forwardlook statement forwardlook statement involv known unknown risk uncertainti may caus compani actual result level activ perform achiev materi differ express impli forwardlook statement import factor may caus contribut differ includ whether physician patient key decis maker accept clinic trial result compani abil success compet potenti competitor may discov develop commerci compet product success whether third parti compani reli manufactur support develop commerci raplixa abl fulfil oblig compani abl establish maintain arrang factor set forth risk factor detail time time compani period report registr statement file secur exchang commiss includ without limit risk factor detail compani annual report form 10k file sec march 2 2015 incorpor herein refer compani specif disclaim oblig updat forwardlook statementsth medicin companymediabob laverti 1 presid communicationsrobertlavertythemedcocomorinvestorrelationsneera dahiya ravindran md 1 9732906044 vicepresid investor relat strateg plan neeraravindranthemedcocom 